- 2 days ago
- 8 min read
Key Takeaways |
A child with relapsed acute lymphoblastic leukemia (ALL) achieved complete remission within 4 weeks of a single HLA-haploidentical allogeneic CAR-T infusion, and remained cancer-free at the 3-year follow-up mark — the longest reported cancer-free survival for this specific protocol in China at the time. |
The "Beijing Protocol" solves CAR-T's biggest access problem: donor scarcity. Unlike standard autologous CAR-T (which requires collecting a patient's own T cells), this approach uses T cells from a half-matched (haploidentical) relative — a parent, child, or sibling — meaning nearly any patient with a living family member can be a candidate. |
No gene editing or cell freezing required. The protocol was designed to skip two of the most expensive and technically fragile steps in conventional allogeneic CAR-T manufacturing, simplifying production and potentially lowering cost and turnaround time. |
Complete remission rates above 90% have been reported across multiple 3A-grade trial sites in Beijing, including in rare leukemia subtypes and cases with organ metastasis. |
Introduction
Most people who've heard of CAR-T cell therapy know the story of Emily Whitehead — the first pediatric patient treated with CAR-T in the US in 2012, whose recovery made global headlines. Fewer people know that China has its own parallel milestone: a Beijing-based protocol that made allogeneic CAR-T — CAR-T from a donor, not the patient — accessible to patients who have no other option.
This is the case of Jiachen (pseudonym), a Chinese child with acute lymphoblastic leukemia who relapsed after chemotherapy and a bone marrow transplant. In August 2016, he received a single infusion of HLA-haploidentical allogeneic CAR-T cells under a protocol developed by Professor Xu Zhongwei's team at Peking University, working with a hematology research team at a leading 3A-grade academic hospital in Beijing. Four weeks later, he was in complete molecular remission. As of the 3-year follow-up in August 2019, he remained cancer-free with no further anti-leukemia treatment — a result his medical team described as a clinical cure.
This article goes deeper on this specific protocol as part of our ongoing coverage of CAR-T cancer treatment options, countries, and outcomes — for readers who want the full picture on cost, eligibility, and how China's CAR-T ecosystem compares internationally.
The Patient's Journey Before CAR-T
Patient: Jiachen (pseudonym), diagnosed as a child
Diagnosis: Acute lymphoblastic leukemia (ALL)
Treatment history: Chemotherapy, followed by bone marrow (hematopoietic stem cell) transplantation
The setback: Despite transplant, the leukemia relapsed — a scenario where standard treatment options narrow considerably and prognosis becomes more guarded
How the family found the option: After learning that Professor Xu Zhongwei's team was running a CAR-T clinical trial in collaboration with a leading hematology institute at a top-tier 3A-grade hospital in Beijing, the family traveled to Beijing to pursue it
"After undergoing chemotherapy, bone marrow transplantation, and other treatments, he relapsed. In despair, we learned that Professor Xu's team was conducting a CAR-T clinical trial in collaboration with a leading hematology institute in Beijing, so we immediately came to Beijing for treatment," Jiachen's mother said.
The Medical Team & the Innovation Behind It
A leading hematology institute at a 3A-grade academic hospital in Beijing — one of China's leading centers for hematologic malignancy treatment and stem cell transplantation, and a long-standing collaborator on haploidentical transplant protocols.
Professor Xu Zhongwei — a specially appointed professor in the Department of Immunology, School of Basic Medical Sciences, Peking University. Xu has worked in CAR-T cell development since 1996 and was the first project manager for CD19-CAR-T at Dr. Carl June's lab at the University of Pennsylvania — the same lab that developed the CAR-T therapy used to treat Emily Whitehead, one of the first successful pediatric CAR-T cases in the US. Xu returned to China in 2016 to lead allogeneic CAR-T research.
A co-leading hematology professor at the same institute co-developed the protocol alongside Xu Zhongwei's team.
What makes the "Beijing Protocol" different: Standard CAR-T therapy is autologous — it uses the patient's own T cells, which must be collected, genetically modified, and re-infused. This isn't possible for every patient, and donor-based (allogeneic) CAR-T has historically required a closely HLA-matched donor, gene editing to prevent the donor cells from attacking the patient's body (graft-versus-host disease), and cryopreservation. The Beijing Protocol was designed to work around these barriers:
Uses a half-matched (haploidentical) relative — parent, child, or sibling — as the T-cell donor, rather than requiring a fully matched donor
Skips gene editing and cell freezing/thawing steps
Deliberately allows a controlled, moderate graft-versus-leukemia effect, which may enhance the anti-tumor response
According to the treatment team, this combination is what's allowed them to treat patients who previously had no viable CAR-T pathway at all, since most people have at least one relative who is a half-match.
Treatment Timeline
Stage | Outcome |
August 2016 | Single infusion of HLA-haploidentical allogeneic CAR-T cells |
4 weeks post-infusion | Molecular biology and morphological testing confirmed complete remission |
Following 3 years | Regular monitoring, no additional anti-leukemia treatment; leukemia cells undetectable |
August 2019 (3-year mark) | Jiachen's attending hematologist confirmed the case met criteria for clinical cure |
Xu Zhongwei has noted a key distinction between this case and internationally known CAR-T cases like Emily Whitehead's: Jiachen's treatment was non-gene-edited allogeneic CAR-T — an approach that, at the time, represented a novel direction internationally, not just domestically.
Beyond a Single Case: Broader Trial Results
Jiachen's case isn't presented as an isolated result. Xu Zhongwei's team has run parallel haploidentical allogeneic CAR-T trials in collaboration with multiple other 3A-grade children's and hematology hospitals, exploring different targets and technical approaches. Across these trials, the team has reported complete remission rates above 90% in multiple patients, including cases involving rare leukemia subtypes and patients with myocardial (heart) metastases.
It's worth being precise about what this means: a "complete remission rate above 90%" describes molecular/morphological remission at a defined post-treatment checkpoint within these specific trial cohorts — not a guaranteed cure rate for all ALL patients, and not necessarily directly comparable to remission rates reported for other CAR-T protocols or patient populations. As with any cellular therapy, individual outcomes depend on disease subtype, prior treatment burden, donor match quality, and how early relapse is caught.
Why This Pediatric CAR-T Case Is Not Just a Story
Cell and gene therapy coverage tends to center on US institutions and FDA-approved products (Kymriah, Yescarta, and others). The Beijing Protocol is a useful counterpoint: it shows a China-originated allogeneic CAR-T approach solving a real access problem — donor scarcity — years before broader global attention turned to allogeneic ("off-the-shelf") CAR-T as the next frontier of cell therapy.
For patients and families researching CAR-T options today, cases like Jiachen's illustrate two practical points worth knowing:
China's CAR-T research base is not new or experimental at the margins — it includes protocols developed and refined at major 3A-grade academic hospitals over a decade, with published long-term follow-up.
Allogeneic approaches matter for patients without a straightforward treatment path — not every patient is a good candidate for autologous CAR-T (due to poor T-cell quality after heavy prior chemotherapy, for example, or lack of time to manufacture a personalized product during aggressive relapse). Donor-based options widen who can be treated at all.
This case is presented for its clinical and scientific significance. For international patients and families evaluating CAR-T therapy in China today, ChinaCureLink helps navigate hospital selection, eligibility screening, and logistics — see our full guide to CAR-T treatment countries, costs, and options for what the process looks like end to end.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
Frequently Asked Questions
What is the "Beijing Protocol" for CAR-T therapy?
It's an HLA-haploidentical allogeneic CAR-T protocol developed by a Peking University research team working with a leading hematology institute at a 3A-grade hospital in Beijing. It allows CAR-T cells to be sourced from a half-matched relative rather than the patient or a fully matched donor, without requiring gene editing or cell cryopreservation.
Is allogeneic CAR-T different from standard CAR-T?
Yes. Standard (autologous) CAR-T uses the patient's own T cells. Allogeneic CAR-T uses T cells from a donor — in the Beijing Protocol's case, a half-matched family member — which can make treatment possible for patients who can't produce a viable autologous product.
How long did it take for the patient in this case to go into remission?
Complete remission was confirmed by molecular and morphological testing 4 weeks after a single CAR-T infusion.
Does this mean CAR-T therapy in China doesn't require a matched donor?
For protocols like the Beijing Protocol, yes — a half-matched (haploidentical) relative, such as a parent, child, or sibling, can serve as the donor, which removes the need to find a fully HLA-matched donor.
Is this the same as the CAR-T therapy approved in the US (Kymriah, Yescarta, etc.)?
No — Kymriah and Yescarta are FDA-approved autologous CAR-T products. The Beijing Protocol is a donor-based (allogeneic) academic protocol developed and used in trials at 3A-grade Chinese hospitals. Both fall under the broader CAR-T therapy category but differ in cell source and manufacturing approach.
Where can I learn about CAR-T treatment costs and options in China?
References
Gao Chang'an & Wu Jingyan, "The 'Beijing Protocol' Opens the Path for Cell Immunotherapy in China", China Science Daily, August 26, 2019 — original source case report. (Note: the original published news report names the specific Beijing hospital and hematology institute involved; hospital name is intentionally omitted from the body of this article per internal editorial policy.)
Xu, Z. et al., "Update of the 'Beijing Protocol' haplo-identical hematopoietic stem cell transplantation", Bone Marrow Transplantation (Nature).
"Haploidentical transplants with a G-CSF/ATG-based protocol: Experience from China", ScienceDirect.
"Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT", ClinicalTrials.gov — NCT05921318.
About ChinaCureLink
ChinaCureLink helps patients acrossthe world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia-Pacific, bringing the same standard of expert care coordination to every patient we serve.
Disclaimer
This article is for informational purposes only and does not constitute medical or financial advice. Treatment eligibility, protocols, and outcomes vary by individual patient and disease subtype. Please confirm specifics with a qualified oncologist or a ChinaCureLink coordinator before making treatment decisions.
Comments